Product nameAnti-GABARAPL1 antibody - N-terminal
See all GABARAPL1 primary antibodies
DescriptionRabbit polyclonal to GABARAPL1 - N-terminal
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Mouse, Rat, Human
Predicted to work with: Guinea pig, Cow, Pig, Xenopus laevis, Rhesus monkey
Synthetic peptide within Human GABARAPL1 (N terminal). The exact sequence is proprietary. Conjugated to a protein carrier.
Database link: Q9H0R8
- ICC/IF: Chloroquine treated HeLa cells. WB: U-87 MG and SK-N-SH whole cell extracts; mouse and rat brain tissue extracts.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.025% Proclin
Constituents: PBS, 1% BSA, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab229558 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/3000. Predicted molecular weight: 14 kDa.|
|ICC/IF||1/100 - 1/1000.|
FunctionUbiquitin-like modifier that increases cell-surface expression of kappa-type opioid receptor through facilitating anterograde intracellular trafficking of the receptor. Involved in formation of autophagosomal vacuoles. Whereas LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation.
Tissue specificityUbiquitous. Expressed at very high levels in the brain, heart, peripheral blood leukocytes, liver, kidney, placenta and skeletal muscle. Expressed at very low levels in thymus and small intestine. In the brain, expression is particularly intense in motoneurons in the embryo and in neurons involved in somatomotor and neuroendocrine functions in the adult, particularly in the substantia nigra pars compacta.
Sequence similaritiesBelongs to the ATG8 family.
modificationsThe precursor molecule is cleaved by ATG4B to form the cytosolic form, GABARAPL1-I. This is activated by APG7L/ATG7, transferred to ATG3 and conjugated to phospholipid to form the membrane-bound form, GABARAPL1-II (By similarity). ATG4B also mediates the delipidation required for GABARAPL1 recycling when autophagosomes fuse with lysosomes.
The Legionella effector RavZ is a deconjugating enzyme that produces an ATG8 product that would be resistant to reconjugation by the host machinery due to the cleavage of the reactive C-terminal glycine.
Cellular localizationCytoplasm > cytoskeleton. Cytoplasmic vesicle membrane. Endoplasmic reticulum. Golgi apparatus. Cytoplasmic vesicle > autophagosome.
- Information by UniProt
- APG8 like antibody
- APG8L antibody
- ATG8 antibody
HeLa (human epithelial cell line from cervix adenocarcinoma) cells stained for GABARAPL1 (green) using ab229558 (1/500 dilution) in ICC/IF. Cells were fixed in 4% paraformaldehyde at RT for 15 minutes. Counterstain: Hoechst 33342 (blue) and phalloidin, a cytoskeleton marker (red)
All lanes : Anti-GABARAPL1 antibody - N-terminal (ab229558) at 1/1000 dilution
Lane 1 : U-87 MG (Human glioblastoma-astrocytoma epithelial cell line) whole cell extracts at 60 µg
Lane 2 : SK-N-SH (Human neuroblastoma cell line) whole cell extracts at 60 µg
Lane 3 : Mouse brain tissue extracts at 15 µg
Lane 4 : Rat brain tissue extracts at 15 µg
Developed using the ECL technique.
Predicted band size: 14 kDa
ab229558 has not yet been referenced specifically in any publications.